- Home
- FIGS vs ABUS Comparison
FIGS vs ABUS Comparison
Compare FIGS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FIGS
- ABUS
- Stock Information
- Founded
- FIGS 2013
- ABUS N/A
- Country
- FIGS United States
- ABUS United States
- Employees
- FIGS N/A
- ABUS N/A
- Industry
- FIGS Apparel
- ABUS Biotechnology: Pharmaceutical Preparations
- Sector
- FIGS Consumer Discretionary
- ABUS Health Care
- Exchange
- FIGS Nasdaq
- ABUS Nasdaq
- Market Cap
- FIGS 793.0M
- ABUS 725.9M
- IPO Year
- FIGS 2021
- ABUS N/A
- Fundamental
- Price
- FIGS $4.71
- ABUS $3.46
- Analyst Decision
- FIGS Hold
- ABUS Strong Buy
- Analyst Count
- FIGS 6
- ABUS 4
- Target Price
- FIGS $5.40
- ABUS $5.50
- AVG Volume (30 Days)
- FIGS 3.5M
- ABUS 837.4K
- Earning Date
- FIGS 11-07-2024
- ABUS 11-06-2024
- Dividend Yield
- FIGS N/A
- ABUS N/A
- EPS Growth
- FIGS N/A
- ABUS N/A
- EPS
- FIGS 0.05
- ABUS N/A
- Revenue
- FIGS $548,644,000.00
- ABUS $6,742,000.00
- Revenue This Year
- FIGS $2.82
- ABUS N/A
- Revenue Next Year
- FIGS $3.86
- ABUS N/A
- P/E Ratio
- FIGS $86.60
- ABUS N/A
- Revenue Growth
- FIGS 0.55
- ABUS N/A
- 52 Week Low
- FIGS $4.30
- ABUS $1.79
- 52 Week High
- FIGS $7.98
- ABUS $4.72
- Technical
- Relative Strength Index (RSI)
- FIGS 31.99
- ABUS 30.63
- Support Level
- FIGS $4.65
- ABUS $3.42
- Resistance Level
- FIGS $5.10
- ABUS $3.81
- Average True Range (ATR)
- FIGS 0.28
- ABUS 0.16
- MACD
- FIGS -0.09
- ABUS -0.04
- Stochastic Oscillator
- FIGS 12.61
- ABUS 7.41
About FIGS FIGS Inc.
FIGS Inc is a healthcare apparel company. The Company designs and sells scrubwear and non-scrubwear, such as outerwear, underscrubs, footwear, compression socks, lab coats, loungewear and other apparel. The Company markets and sells its products in the United States. Sales are generated through the Company's digital platforms.
About ABUS Arbutus Biopharma Corporation
Arbutus Biopharma Corp is a biopharmaceutical company. The company discovers, develops, and commercializes cures for patients suffering from Hepatitis B infection. The company is focused on developing a portfolio of drug candidates with multiple mechanisms of action and is also involved in licensing Lipid nanoparticle technology.